Characteristic | Entire cohort no. (%)a | Univariate Cox analysis | |||
---|---|---|---|---|---|
5-year OS | 5-year FFS | ||||
HR (95% CI) | P | HR (95% CI) | P | ||
Age, years | Â | Â | Â | Â | Â |
< 37 | 1175 (23.3) | Reference |  | Reference |  |
38–43 | 1141 (22.7) | 1.30 (1.01–1.67) | 0.043 | 1.11 (0.93–1.33) | 0.247 |
44–51 | 1380 (27.4) | 1.35 (1.06–1.71) | 0.016 | 1.06 (0.89–1.27) | 0.483 |
 ≥ 52 | 1339 (26.6) | 2.00 (1.59–2.51) |  < 0.001 | 1.17 (0.98–1.39) | 0.079 |
Gender | Â | Â | Â | Â | Â |
Male | 3697 (73.4) | Reference | Â | Reference | Â |
Female | 1338 (26.6) | 0.63 (0.57–0.84) |  < 0.001 | 0.74 (0.64–0.86) |  < 0.001 |
Histological type | Â | Â | Â | Â | Â |
WHO type I–II | 116 (2.3) | Reference |  | Reference |  |
WHO type III | 4919 (97.7) | 0.55 (0.37–0.80) | 0.002 | 0.51 (0.37–0.68) |  < 0.001 |
T category (8th edition) | Â | Â | Â | Â | Â |
T1 | 263 (5.2) | Reference | Â | Reference | Â |
T2 | 364 (7.2) | 1.26 (0.80–2.00) | 0.322 | 1.20 (0.84–1.71) | 0.327 |
T3 | 3049 (60.6) | 1.02 (0.70–1.48) | 0.936 | 1.01 (0.75–1.35) | 0.973 |
T4 | 1359 (27.0) | 1.66 (1.13–2.44) | 0.010 | 1.51 (1.12–2.04) | 0.007 |
N category (8th edition) | Â | Â | Â | Â | Â |
N0 | 456 (9.1) | Reference | Â | Reference | Â |
N1 | 2335 (46.4) | 1.67 (1.14–2.46) | 0.009 | 1.59 (1.19–2.11) | 0.002 |
N2 | 1455 (28.9) | 2.50 (1.70–3.69) |  < 0.001 | 2.23 (1.67–2.98) |  < 0.001 |
N3 | 789 (15.7) | 3.57 (2.41–5.31) |  < 0.001 | 3.00 (2.22–4.03) |  < 0.001 |
Treatmentb | Â | Â | Â | Â | Â |
IC + CCRT | 2420 (48.0) | – | – | – | – |
IC + RT | 543 (10.8) | – | – | – | – |
CCRT | 2072 (41.2) | – | – | – | – |
IC interruption during the Spring Festival | |||||
No | 2542 (85.8) | Reference | Â | Reference | Â |
Yes | 421 (14.2) | 1.06 (0.81–1.38) | 0.692 | 0.94 (0.75–1.17) | 0.565 |
RT interruption during the Spring Festival | Â | Â | Â | Â | |
No | 4473 (88.8) | Reference | Â | Reference | Â |
Yes | 562 (11.2) | 1.34 (1.08–1.67) | 0.009 | 1.22 (1.02–1.46) | 0.033 |
EBV DNA titer, copies/mL | Â | Â | Â | Â | Â |
< 2000 | 2197 (43.6) | Reference |  | Reference |  |
≥ 2000 | 2838 (56.4) | 2.08 (1.75–2.47) |  < 0.001 | 2.03 (1.78–2.32) |  < 0.001 |
LDH, U/L | Â | Â | Â | Â | Â |
< 250 | 4651 (92.4) | Reference |  | Reference |  |
≥ 250 | 384 (7.6) | 2.07 (1.66–2.59) |  < 0.001 | 1.67 (1.38–2.03) |  < 0.001 |
CRP, mg/L | Â | Â | Â | Â | Â |
≤ 3.00 | 3387 (67.3) | Reference |  | Reference |  |
> 3.00 | 1648 (32.7) | 1.60 (1.37–1.86) |  < 0.001 | 1.31 (1.16–1.48) |  < 0.001 |
Anemia | Â | Â | Â | Â | Â |
No | 4817 (95.7) | Reference | Â | Reference | Â |
Yes | 218 (4.3) | 1.44 (1.04–2.00) | 0.028 | 1.15 (0.87–1.53) | 0.320 |
Family history of cancer | Â | Â | Â | Â | Â |
No | 3788 (75.2) | Reference | Â | Reference | Â |
Yes | 1247 (24.8) | 0.92 (0.77–1.11) | 0.376 | 1.01 (0.88–1.16) | 0.883 |
Cigarette smoking | Â | Â | Â | Â | Â |
No | 3185 (63.3) | Reference | Â | Reference | Â |
Yes | 1850 (36.7) | 1.34 (1.15–1.57) |  < 0.001 | 1.26 (1.12–1.42) |  < 0.001 |
Alcohol consumption | Â | Â | Â | Â | Â |
No | 4330 (86.0) | Reference | Â | Reference | Â |
Yes | 705 (14.0) | 1.14 (0.92–1.41) | 0.230 | 1.07 (0.90–1.27) | 0.436 |
Comorbidity | Â | Â | Â | Â | Â |
No | 3936 (78.2) | Reference | Â | Reference | Â |
Yes | 1099 (21.8) | 1.08 (0.90–1.30) | 0.403 | 1.04 (0.90–1.20) | 0.633 |